OSEP Stock Overview
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OSE Immunotherapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.52 |
| 52 Week High | €7.10 |
| 52 Week Low | €5.30 |
| Beta | 1.01 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -17.92% |
| 3 Year Change | -9.51% |
| 5 Year Change | n/a |
| Change since IPO | 34.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| OSEP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.3% |
| 1Y | -17.9% | -30.1% | -0.8% |
Return vs Industry: OSEP exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: OSEP underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| OSEP volatility | |
|---|---|
| OSEP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OSEP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OSEP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 60 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
| OSEP fundamental statistics | |
|---|---|
| Market cap | €69.51m |
| Earnings (TTM) | -€17.76m |
| Revenue (TTM) | €18.30m |
3.8x
P/S Ratio-3.9x
P/E RatioIs OSEP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSEP income statement (TTM) | |
|---|---|
| Revenue | €18.30m |
| Cost of Revenue | €0 |
| Gross Profit | €18.30m |
| Other Expenses | €36.06m |
| Earnings | -€17.76m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 100.00% |
| Net Profit Margin | -97.04% |
| Debt/Equity Ratio | 123.5% |
How did OSEP perform over the long term?
See historical performance and comparison